Liver fibrosis is a key pathologic feature associated with the majority of chronic liver diseases. Current diagnostic tools include biopsy and blood analyte panels; however, biopsy is subject to sampling and inter/intra-observer variance, and blood analyte surveys lack sufficient sensitivity and specificity for early stage disease detection.
To address this gap army researchers have developed a biomarker selection method to identify genes correlated to liver fibrosis. The resulting gene activation patterns have been validated as diagnostic correlates within rat models of toxic liver fibrosis.
This technology has potential applications for pre-clinical and clinical diagnostics, anti-fibrotic drug development, general toxicity screening for drug development, and adverse outcome pathway framework development.
- Early detection capabilities–Allows for earlier detection of fibrotic injury when compared to current methods
- Improved progression tracking–Allows for better tracking and resolution of disease status and progression
- Personalized diagnostic platform–Addresses inter-individual variations, thus allowing for a more personalized diagnostic platform
- Pending US patent application is available for license
- Potential for collaborative research with top DoD scientists and engineers